Epigenetic dysregulation is a common feature of most cancers, often occurring directly
through alteration of epigenetic machinery. Over the last several years, a new generation of …

Epigenetic drug discovery field has evidenced significant advancement in the recent times.
A plethora of small molecule inhibitors have progressed to clinical stage investigations and …

Epigenetic processes are essential for normal development and the maintenance of tissue-
specific gene expression in mammals. Changes in gene expression and malignant cellular …

Abstract Purpose of Review Enhancer of Zeste Homolog 2 (EZH2) is histone
methyltransferase and catalyzes the methylation of histone 3 lysine 27, a mark of …

Recurrent somatic mutations in the BRG1/BRM-associated factor (BAF) chromatin
remodeling complex subunit ARID1A occur frequently in advanced urothelial, endometrial …

Purpose: Both gain-of-function enhancer of zeste homolog 2 (EZH2) mutations and
inactivating histone acetyltransferases mutations, such as CREBBP and EP300, have been …

The tumor immune microenvironment (TIME), an immunosuppressive niche, plays a pivotal
role in contributing to the development, progression, and immune escape of various types of …

Introduction PRC2 is a histone methyltransferase complex associated with several cancer
types. Tazemetostat was recently approved as the first inhibitor targeting the catalytic subunit …

Histone lysine methylation is a post-translational modification that plays a key role in the
epigenetic regulation of a broad spectrum of biological processes. Moreover, the …

Follicular lymphoma (FL) is a heterogeneous disease with varying prognosis owing to
differences in clinical, laboratory, and disease parameters. Although generally considered …